<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717375</url>
  </required_header>
  <id_info>
    <org_study_id>BND-22-001</org_study_id>
    <nct_id>NCT04717375</nct_id>
  </id_info>
  <brief_title>Study of BND-22 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2, Dose Escalation and Expansion Study of the Safety, Tolerability, and Anti-tumor Activity of BND-22 Administered Alone and in Combination With Pembrolizumab or With Cetuximab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biond Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biond Biologics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, dose escalation and expansion study designed to evaluate&#xD;
      the safety, tolerability, and preliminary anti-tumor activity of BND-22 administered alone&#xD;
      and in combination with pembrolizumab or with cetuximab. The study will enroll advanced&#xD;
      cancer patients with unresectable or metastatic disease who are refractory to or are not&#xD;
      candidates for standard approved therapy and will be comprised of two parts - an initial &quot;3 +&#xD;
      3&quot; dose escalation phase followed by a dose expansion phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Incidence of treatment-emergent adverse events (TEAEs) dose limiting toxicities (DLT)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Incidence of TEAEs meeting protocol defined DLT criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Incidence of treatment-emergent adverse events</measure>
    <time_frame>Through study completion, an average of 5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Objective Response Rate (ORR) per RECIST v1.1</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>Proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum observed plasma concentration [Cmax]</measure>
    <time_frame>Through study completion, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Maximum observed plasma concentration [Cmax]</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Terminal elimination half-life [T1/2]</measure>
    <time_frame>Through study completion, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Terminal elimination half-life [T1/2]</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the plasma concentration-time curve [AUC]</measure>
    <time_frame>Through study completion, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area under the plasma concentration-time curve [AUC]</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Incidence of anti-drug antibodies (ADA)</measure>
    <time_frame>Through study completion, an average of 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Incidence of anti-drug antibodies (ADA)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Progression Free Survival</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>Time from the date of first dose of study drug to the date of first documented disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of Response</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Duration between first documentation of CR or PR to first documentation of disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Incidence of Serious Adverse Events and Adverse Events</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>BND-22 Dose Escalation (Sub-Part 1A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard &quot;3 + 3&quot; dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-22 will be administered intravenously (IV), every 2 weeks (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BND-22 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard &quot;3 + 3&quot; dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-22 and pembrolizumab will be administered intravenously (IV), every 3 weeks (Q3W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BND-22 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard &quot;3 + 3&quot; dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-22 and cetuximab will be administered intravenously (IV), every 2 weeks (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BND-22 Dose Expansion (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will include three expansion cohorts enrolling patients with advanced stage squamous cell carcinoma of the head and neck, gastric or gastroesophageal junction adenocarcinoma, and non-small cell lung cancer. Enrollment will start after the RP2D of BND-22 has been established. BND-22 will be administered intravenously (IV), every 2 weeks (Q2W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BND-22</intervention_name>
    <description>Monoclonal antibody administered intravenously</description>
    <arm_group_label>BND-22 Dose Escalation (Sub-Part 1A)</arm_group_label>
    <arm_group_label>BND-22 Dose Expansion (Part 2)</arm_group_label>
    <arm_group_label>BND-22 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)</arm_group_label>
    <arm_group_label>BND-22 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Monoclonal antibody administered intravenously</description>
    <arm_group_label>BND-22 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Monoclonal antibody administered intravenously</description>
    <arm_group_label>BND-22 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with unresectable or metastatic disease who are refractory to or are not&#xD;
             candidates for standard approved therapy&#xD;
&#xD;
          -  Histologic confirmation of malignancy&#xD;
&#xD;
          -  Measurable disease per RECIST v1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG) of 0 or 1&#xD;
&#xD;
          -  Participants must have adequate organ function as defined by lab tests&#xD;
&#xD;
          -  Part 1: Following tumor types: Breast cancer, cervical cancer, colorectal cancer,&#xD;
             adenocarcinoma or squamous cell carcinoma of the esophagus, gastric or&#xD;
             gastroesophageal junction adenocarcinoma, squamous cell carcinoma of the head and&#xD;
             neck, hepatobiliary cancers (hepatocellular carcinoma (HCC), gallbladder cancer,&#xD;
             cholangiocarcinoma), non-small cell lung cancer, renal cell carcinoma, squamous cell&#xD;
             carcinoma of the skin, or urothelial carcinoma&#xD;
&#xD;
          -  Part 2: Following tumor types: Squamous cell carcinoma of the head and neck, Gastric&#xD;
             or gastroesophageal junction adenocarcinoma, Non-small cell lung cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease&#xD;
&#xD;
          -  Condition requiring systemic treatment with either corticosteroids or other&#xD;
             immunosuppressive medications&#xD;
&#xD;
          -  Brain or leptomeningeal metastases&#xD;
&#xD;
          -  Known history of positive test for HIV&#xD;
&#xD;
          -  Non-HCC patients: acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV);&#xD;
             HCC patients: untreated active HBV or dual infection with HBV/HCV&#xD;
&#xD;
          -  Participants after solid organ or allogeneic hematopoietic stem cell transplant&#xD;
&#xD;
          -  History of life-threatening toxicity related to prior immune therapy&#xD;
&#xD;
          -  History of life-threatening toxicity related to prior cetuximab or other anti-EGFR&#xD;
             antibodies (for Sub-Part 1C)&#xD;
&#xD;
          -  Unstable or deteriorating cardiovascular disease within the previous 6 months&#xD;
&#xD;
          -  Any major surgery within 4 weeks of study drug administration&#xD;
&#xD;
          -  Prior/Concomitant Therapy:&#xD;
&#xD;
          -  Cytotoxic/Non-cytotoxic anti-cancer agents, unless at least 4 weeks have elapsed from&#xD;
             last dose&#xD;
&#xD;
          -  Use of other investigational drugs within 28 days&#xD;
&#xD;
          -  Prior treatment with macrophage or natural killer (NK) cells activating therapies&#xD;
&#xD;
          -  Administration of a live attenuated vaccine within 28 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Itay Friedman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Biond Biologics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Itay Friedman, MD</last_name>
    <phone>+972-48844337</phone>
    <email>itay@biondbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitesh Borad, MD</last_name>
      <phone>480-342-4800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Palma</last_name>
      <phone>203-200-2486</phone>
      <email>Ingrid.palma@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liat Rapaport</last_name>
      <phone>972-4-777-6731</phone>
      <email>L_Rapaport@rambam.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gal Medalia</last_name>
      <phone>972-3-937-8023</phone>
      <email>Galmed@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilanit Redinsky</last_name>
      <phone>972-3-530-4498</phone>
      <email>Ilanit.Redinsky@sheba.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Limor Ben Zvi</last_name>
      <phone>972-3-697-3193</phone>
      <email>limorb@tlvmc.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

